secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2026-09-14T20:07:12+00:00
Accession:  0001628280-26-061834
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum's MOONLIGHT-1 Phase 2 trial fails primary endpoint in MDD
-------------------------------------------------------------------

- MOONLIGHT-1 Phase 2 trial of JNJ-5120/PIPE-307 in MDD did not meet primary efficacy endpoint.
- Primary endpoint: MADRS total score change at Day 5 vs placebo; no new safety signals.
- JNJ-5120/PIPE-307 developed by J&J under global license; J&J evaluating exploratory endpoints.
- Randomized, double-blind, placebo-controlled proof-of-concept trial in adult MDD (NCT06785012).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026061834/0001628280-26-061834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000162828026061834/ctnm-20260914.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-061834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer